The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening

Reviews in Medical Virology

Volumn 21, Issue 3, 2011, Pages 139-153

  Schmeink, Channa E ^a   Bekkers, Ruud L M ^a   Massuger, Leon F A G ^a   Melchers, Willem J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; NONHUMAN; PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; TAMPON; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SELF CARE; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS;

EID: 79955396599     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.686     Document Type: Review

References (102)

1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. Journal of the National Cancer Institute 1995; 87(11): 796-802.
2. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. Journal of the National Cancer Institute 1993; 85(12): 958-964.
3. Bulk S, Bulkmans NW, Berkhof J, et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. International Journal of Cancer 2007; 121(2): 361-367.
4. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35years: results at recruitment for a randomised controlled trial. The Lancet Oncology 2006; 7(7): 547-555.
5. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer 2006; 119(5): 1095-1101.
6. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. The New England Journal of Medicine 2007; 357(16): 1589-1597.
7. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370(9601): 1764-1772.
8. Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. British Journal of Cancer 2005; 92(9): 1800-1802.
9. Daponte A, Tsezou A, Oikonomou P, et al. Use of real-time PCR to detect human papillomavirus-16 viral loads in vaginal and urine self-sampled specimens. Clinical Microbiology and Infection 2008; 14(6): 619-621.
10. Harper DM, Noll WW, Belloni DR, Cole BF. Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed-biologic concordance and women's preferences. American Journal of Obstetrics and Gynecology 2002; 186(3): 365-373.
11. Dzuba IG, Diaz EY, Allen B, et al. The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. Journal of Women's Health Gender-Based Medicine 2002; 11(3): 265-275.
12. Jones HE, Wiegerinck MA, Nieboer TE, Mol BW, Westhoff CL. Women in the Netherlands prefer self-sampling with a novel lavaging device to clinician collection of specimens for cervical cancer screening. Sexually Transmitted Diseases 2008; 35(11): 916-917.
13. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. Journal of Clinical Pathology 2002; 55(6): 435-439.
14. Waller J, McCaffery K, Forrest S, et al. Acceptability of unsupervised HPV self-sampling using written instructions. Journal of Medical Screening 2006; 13(4): 208-213.
15. Gok M, Heideman DA, van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010; 340: c1040.
16. Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecologic Oncology 2007; 105(2): 530-535.
17. Ogilvie GS, Patrick DM, Schulzer M, et al. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sexually Transmitted Infections 2005; 81(3): 207-212.
18. Stewart DE, Gagliardi A, Johnston M, et al. Self-collected samples for testing of oncogenic human papillomavirus: a systematic review. Journal of Obstetrics and Gynaecology Canada 2007; 29(10): 817-828.
19. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007 8; 370(9590): 890-907.
20. Berkhof J, de Bruijne MC, Zielinski GD, Meijer CJ. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. International Journal of Cancer 2005; 115(2): 268-275.
21. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Archives of Medical Research 2009; 40(6): 478-485.
22. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44, 102 women. International Journal of Cancer 2004; 110(1): 94-101.
23. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. Journal of the National Cancer Institute 2009; 101(23): 1612-1623.
24. Cuzick J, Sasieni P, Davies P, et al. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. British Journal of Cancer 2000; 83(5): 561-565.
25. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. The Lancet Oncology 2010; 11(3): 249-257.
26. Davies P, Arbyn M, Dillner J, et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. International Journal of Cancer 2006; 118(4): 791-796.
27. Clavel C, Cucherousset J, Lorenzato M, et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. British Journal of Cancer 2004; 90(9): 1803-1808.
28. Shi JF, Belinson JL, Zhao FH, et al. Human papillomavirus testing for cervical cancer screening: results from a 6-year prospective study in rural China. American Journal of Epidemiology 2009; 170(6): 708-716.
29. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. Journal of the National Cancer Institute 2003; 95(1): 46-52.
30. Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. Journal of Clinical Pathology 2005; 58(9): 946-950.
31. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362(9399): 1871-1876.
32. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
33. Ronco G, Segnan N. HPV testing for primary cervical cancer screening. Lancet 2007; 370(9601): 1740-1742.
34. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. Journal of the National Cancer Institute 2009; 101(2): 88-99.
35. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26 Suppl 10: K29-K41.
36. Brink AA, Snijders PJ, Meijer CJ, Berkhof J, Verheijen RH. HPV testing in cervical screening. Best Practice & Research. Clinical Obstetrics & Gynaecology 2006; 20(2): 253-266.
37. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30years and older. International Journal of Cancer 2009; 124(3): 516-520.
38. Zhao C, Florea A, Austin RM. Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Archives of Pathology & Laboratory Medicine 2010; 134(1): 103-108.
39. Holanda F, Jr., Castelo A, Veras TM, de Almeida FM, Lins MZ, Dores GB. Primary screening for cervical cancer through self sampling. International Journal of Gynaecology and Obstetrics 2006; 95(2): 179-184.
40. Chang CC, Tseng CJ, Liu WW, et al. Clinical evaluation of a new model of self-obtained method for the assessment of genital human papilloma virus infection in an underserved population. Chang Gung Medical Journal 2002; 25(10): 664-671.
41. Safaeian M, Kiddugavu M, Gravitt PE, et al. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. Sexually Transmitted Diseases 2007; 34(7): 429-436.
42. Morris BJ, Rose BR. Cervical screening in the 21st century: the case for human papillomavirus testing of self-collected specimens. Clinical Chemistry and Laboratory Medicine 2007; 45(5): 577-591.
43. Dannecker C, Siebert U, Thaler CJ, Kiermeir D, Hepp H, Hillemanns P. Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. Annals of Oncology 2004; 15(6): 863-869.
44. Sellors JW, Lorincz AT, Mahony JB, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. Canadian Medical Association Journal 2000; 163(5): 513-518.
45. Lenselink CH, Melchers WJ, Quint WG, et al. Sexual behaviour and HPV infections in 18 to 29year old women in the pre-vaccine era in the Netherlands. PLoS ONE 2008; 3(11): e3743.
46. Baay MF, Verhoeven V, Lambrechts HA, et al. Feasibility of collecting self-sampled vaginal swabs by mail: quantity and quality of genomic DNA. European Journal of Clinical Microbiology & Infectious Diseases 2009; 28(11): 1285-1289.
47. Harper DM, Raymond M, Noll WW, Belloni DR, Duncan LT, Cole BF. Tampon samplings with longer cervicovaginal cell exposures are equivalent to two consecutive swabs for the detection of high-risk human papillomavirus. Sexually Transmitted Diseases 2002; 29(11): 628-636.
48. Harper DM, Hildesheim A, Cobb JL, Greenberg M, Vaught J, Lorincz AT. Collection devices for human papillomavirus. The Journal of Family Practice 1999; 48(7): 531-535.
49. Brink AA, Meijer CJ, Wiegerinck MA, et al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. Journal of Clinical Microbiology 2006; 44(7): 2518-2523.
50. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiology Biomarkers and Prevention 2008; 17(10): 2536-2545.
51. Gravitt PE, Lacey JV, Jr., Brinton LA, et al. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiology Biomarkers and Prevention 2001; 10(2): 95-100.
52. Baldwin S, Santos C, Mendez BE, et al. Comparison of type-specific human papillomavirus data from self and clinician directed sampling. Gynecologic Oncology 2005; 97(2): 612-617.
53. Lack N, West B, Jeffries D, et al. Comparison of non-invasive sampling methods for detection of HPV in rural African women. Sexually Transmitted Infections 2005; 81(3): 239-241.
54. Lenselink CH, de Bie RP, van Hamont D, et al. Detection and genotyping of human papillomavirus in self-obtained cervicovaginal samples by using the FTA cartridge: new possibilities for cervical cancer screening. Journal of Clinical Microbiology 2009; 47(8): 2564-2570.
55. Belinson JL, Hu S, Niyazi M, et al. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: implications for vaginal self-collection. International Journal of Cancer 2010; 127(5): 1151-1157.
56. Stenvall H, Wikstrom I, Backlund I, Wilander E. Accuracy of HPV testing of vaginal smear obtained with a novel self-sampling device. Acta Obstetricia et Gynecologica Scandinavica 2007; 86(1): 16-21.
57. Gustavsson I, Lindell M, Wilander E, Strand A, Gyllensten U. Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV. Journal of Clinical Virology 2009; 46(2): 112-116.
58. Castle PE, Rodriguez AC, Porras C, et al. A comparison of cervical and vaginal human papillomavirus. Sexually Transmitted Diseases 2007; 34(11): 849-855.
59. Castle PE, Schiffman M, Glass AG, et al. Human papillomavirus prevalence in women who have and have not undergone hysterectomies. The Journal of Infectious Diseases 2006; 194(12): 1702-1705.
60. Bhatla N, Dar L, Patro AR, et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiology 2009; 33(6): 446-450.
61. Daponte A, Pournaras S, Mademtzis I, et al. Evaluation of high-risk human papillomavirus types PCR detection in paired urine and cervical samples of women with abnormal cytology. Journal of Clinical Virology 2006; 36(3): 189-193.
62. De Alba I, Anton-Culver H, Hubbell FA, et al. Self-sampling for human papillomavirus in a community setting: feasibility in Hispanic women. Cancer Epidemiology Biomarkers and Prevention 2008; 17(8): 2163-2168.
63. Jones HE, Allan BR, van de Wijgert JH, et al. Agreement between self- and clinician-collected specimen results for detection and typing of high-risk human papillomavirus in specimens from women in Gugulethu, South Africa. Journal of Clinical Microbiology 2007; 45(6): 1679-1683.
64. Karwalajtys T, Howard M, Sellors JW, Kaczorowski J. Vaginal self sampling versus physician cervical sampling for HPV among younger and older women. Sexually Transmitted Infections 2006; 82(4): 337-339.
65. Khanna N, Mishra SI, Tian G, et al. Human papillomavirus detection in self-collected vaginal specimens and matched clinician-collected cervical specimens. International Journal of Gynecological Cancer 2007; 17(3): 615-622.
66. Longatto-Filho A, Roteli-Martins C, Hammes L, et al. Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS study. European Journal of Gynaecological Oncology 2008; 29(4): 327-332.
67. Moscicki AB, Widdice L, Ma Y, et al. Comparison of natural histories of human papillomavirus (HPV) detected by clinician- and self- sampling. International Journal of Cancer 2010; 127(8): 1882-1892.
68. Seo SS, Song YS, Kim JW, Park NH, Kang SB, Lee HP. Good correlation of HPV DNA test between self-collected vaginal and clinician-collected cervical samples by the oligonucleotide microarray. Gynecologic Oncology 2006; 102(1): 67-73.
69. Soisson AP, Reed E, Brown P, et al. Self-test device for cytology and HPV testing in rural Appalachian women: an evaluation. The Journal of Reproductive Medicine 2008; 53(6): 441-448.
70. Sowjanya AP, Paul P, Vedantham H, et al. Suitability of self-collected vaginal samples for cervical cancer screening in periurban villages in Andhra Pradesh, India. Cancer Epidemiology Biomarkers and Prevention 2009; 18(5): 1373-1378.
71. Szarewski A, Cadman L, Mallett S, et al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. Journal of Medical Screening 2007; 14(1): 34-42.
72. Winer RL, Feng Q, Hughes JP, et al. Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32years of age. Sexually Transmitted Diseases 2007; 34(6): 371-377.
73. Hillemanns P, Kimmig R, Huttemann U, Dannecker C, Thaler CJ. Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet 1999; 354(9194): 1970.
74. Wright TC, Jr., Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. The Journal of the American Medical Association 2000; 283(1): 81-86.
75. Petignat P, Hankins C, Walmsley S, et al. Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropositive women. Clinical Infectious Diseases 2005; 41(4): 527-34.
76. Palmisano ME, Gaffga AM, Daigle J, et al. Detection of human papillomavirus DNA in self-administered vaginal swabs as compared to cervical swabs. International Journal of STD & AIDS 2003; 14(8): 560-567.
77. Kahn JA, Slap GB, Huang B, et al. Comparison of adolescent and young adult self-collected and clinician-collected samples for human papillomavirus. Obstetrics and Gynecology 2004; 103(5 Pt 1): 952-959.
78. Agorastos T, Dinas K, Lloveras B, et al. Self-sampling versus physician-sampling for human papillomavirus testing. International Journal of STD & AIDS 2005; 16(11): 727-729.
79. Garcia F, Barker B, Santos C, et al. Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus. Obstetrics and Gynecology 2003; 102(2): 266-272.
80. Coutlee F, Hankins C, Lapointe N. Comparison between vaginal tampon and cervicovaginal lavage specimen collection for detection of human papillomavirus DNA by the polymerase chain reaction. The Canadian Women's HIV Study Group. Journal of Medical Virology 1997; 51(1): 42-47.
81. Lorenzato FR, Singer A, Ho L, et al. Human papillomavirus detection for cervical cancer prevention with polymerase chain reaction in self-collected samples. American Journal of Obstetrics and Gynecology 2002; 186(5): 962-968.
82. Daponte A, Pournaras S, Mademtzis I, et al. Evaluation of HPV 16 PCR detection in self-compared with clinician-collected samples in women referred for colposcopy. Gynecologic Oncology 2006; 103(2): 463-466.
83. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. The Journal of Pathology 2003; 201(1): 1-6.
84. Anhang R, Nelson JA, Telerant R, Chiasson MA, Wright TC, Jr. Acceptability of self-collection of specimens for HPV DNA testing in an urban population. Journal of Womens Health (2002) 2005; 14(8): 721-728.
85. Forrest S, McCaffery K, Waller J, et al. Attitudes to self-sampling for HPV among Indian, Pakistani, African-Caribbean and white British women in Manchester, UK. Journal of Medical Screening 2004; 11(2): 85-88.
86. Barata PC, Mai V, Howlett R, Gagliardi AR, Stewart DE. Discussions about self-obtained samples for HPV testing as an alternative for cervical cancer prevention. Journal of Psychosomatic Obstetrics and Gynaecology 2008; 29(4): 251-257.
87. Howard M, Lytwyn A, Lohfeld L, Redwood-Campbell L, Fowler N, Karwalajtys T. Barriers to acceptance of self-sampling for human papillomavirus across ethnolinguistic groups of women. Canadian Journal of Public Health 2009; 100(5): 365-369.
88. Barbee L, Kobetz E, Menard J, et al. Assessing the acceptability of self-sampling for HPV among Haitian immigrant women: CBPR in action. Cancer Causes & Control 2009; 21(3): 421-431.
89. Szarewski A, Cadman L, Ashdown-Barr L, Waller J. Exploring the acceptability of two self-sampling devices for human papillomavirus testing in the cervical screening context: a qualitative study of Muslim women in London. Journal of Medical Screening 2009; 16(4): 193-198.
90. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. British Journal of Cancer 1996; 73(8): 1001-1005.
91. Bekkers RL, Massuger LF, Bulten J, Melchers WJ. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Reviews in Medical Virology 2004; 14(2): 95-105.
92. Bekkers RL, Meijer CJ, Massuger LF, Snijders PJ, Melchers WJ. Effects of HPV detection in population-based screening programmes for cervical cancer; a Dutch moment. Gynecologic Oncology 2006; 100(3): 451-454.
93. Stenvall H, Wikstrom I, Wilander E. High prevalence of oncogenic human papilloma virus in women not attending organized cytological screening. Acta Dermato-Venereologica 2007; 87(3): 243-245.
94. Sanner K, Wikstrom I, Strand A, Lindell M, Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. British Journal of Cancer 2009; 101(5): 871-874.
95. Wikstrom I, Stenvall H, Wilander E. Attitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening. Acta Obstetricia et Gynecologica Scandinavica 2007; 86(6): 720-725.
96. Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. Journal of Clinical Virology 2005; 32 Suppl 1: S43-S51.
97. Pagliusi SR, Dillner J, Pawlita M, Quint WG, Wheeler CM, Ferguson M. Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays-an update. Vaccine 2006; 24 Suppl 3: S3/193-S3/200.
98. Walraven G, Scherf C, West B, et al. The burden of reproductive-organ disease in rural women in The Gambia, West Africa. Lancet 2001; 357(9263): 1161-1167.
99. Syrjanen K, Naud P, Derchain S, et al. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study. Anticancer Research 2005; 25(5): 3469-3480.
100. Scott ME, Ma Y, Farhat S, Shiboski S, Moscicki AB. Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. Journal of Clinical Immunology 2006; 26(3): 222-232.
101. Wawer MJ, Gray RH, Sewankambo NK, et al. A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. AIDS 1998; 12(10): 1211-1225.
102. Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. International Journal of Gynecological Cancer 2003; 13(6): 819-826.